Anthera Pharmaceuticals Inc (NASDAQ:ANTH) – Analysts at SunTrust Banks issued their Q1 2018 EPS estimates for Anthera Pharmaceuticals in a research report issued to clients and investors on Thursday. SunTrust Banks analyst E. Nash anticipates that the biopharmaceutical company will post earnings of ($0.68) per share for the quarter. SunTrust Banks also issued estimates for Anthera Pharmaceuticals’ Q2 2018 earnings at ($0.68) EPS, Q3 2018 earnings at ($0.67) EPS and Q4 2018 earnings at ($0.65) EPS.
Other research analysts also recently issued research reports about the company. Roth Capital started coverage on Anthera Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $10.00 price objective on the stock. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, ValuEngine raised Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Anthera Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.19.
Institutional investors and hedge funds have recently modified their holdings of the stock. Wedbush Securities Inc. raised its stake in Anthera Pharmaceuticals by 75.8% during the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 31,800 shares during the period. 683 Capital Management LLC bought a new stake in Anthera Pharmaceuticals during the 4th quarter valued at approximately $399,000. Armistice Capital LLC bought a new stake in Anthera Pharmaceuticals during the 4th quarter valued at approximately $1,269,000. Finally, BVF Inc. IL grew its holdings in Anthera Pharmaceuticals by 20.9% during the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after buying an additional 209,896 shares in the last quarter. 16.44% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Anthera Pharmaceuticals Inc to Post Q1 2018 Earnings of ($0.68) Per Share, SunTrust Banks Forecasts (ANTH)” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2018/02/21/anthera-pharmaceuticals-inc-to-post-q1-2018-earnings-of-0-68-per-share-suntrust-banks-forecasts-anth.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.